Acme India cuts public offer to 62.09 lakh shares after placement

Acme India Industries Limited reduced its public offer to 62.09 lakh equity shares after placing 10.80 lakh shares privately at Rs 190 each for Rs 20.52 crore. The revised offer comprises a fresh issue of 54.07 lakh shares and a promoter offer for sale of 8.02 lakh shares, while the final offer price remains undisclosed.

How did Acme India cut its public offer to 62.09 lakh shares?

Acme India reduced the public offer after completing a pre-IPO placement of 10.80 lakh equity shares through private placement. The company, in consultation with the book running lead manager, issued those shares at Rs 190 each, including a Rs 10 face value and Rs 180 premium, for aggregate consideration of Rs 20.52 crore. The document says the placement resulted in a reduced offer size, but does not state the share count before the reduction.

The revised offer is for up to 62.09 lakh equity shares of Rs 10 face value each, for cash at a price marked as unspecified in the offer document. It consists of a fresh issue of up to 54.07 lakh shares and an offer for sale of up to 8.02 lakh shares by promoter selling shareholders. A fresh issue creates new company shares, while an offer for sale consists of existing shares sold by the identified selling shareholders.

The Rs 190 placement price is a disclosed private-placement transaction price, not the final public-offer price. Acme India told placement investors that there was no assurance the issue would proceed or that listing would occur, and that they invested at their own risk. The public offer will use the book-building process, under which bids are collected before the offer price and allotments are finalised.

What does the revised Acme India public offer contain?

Acme India has reserved 3.14 lakh shares for a designated market maker and made up to 58.94 lakh shares available in the net offer to the public. The market-maker reservation is 5.06% of the offer, while the total offer and net offer represent 26.45% and 25.11%, respectively, of post-offer paid-up equity share capital. The distinction matters because public-category allocations apply to the net offer rather than the market-maker reservation.

A market maker is a registered intermediary required to support trading in an SME issue after listing. Acme India states that compulsory market making on BSE SME will continue for at least three years from listing on BSE's Emerge platform. The market maker may buy a shareholder's entire holding where its value is below the minimum contract size, which is the stated arrangement for odd lots.

Qualified institutional buyers, or QIBs, may receive up to 29,44,800 shares, excluding the possible anchor allocation. Acme India and the book running lead manager may allocate up to 60% of the QIB portion to anchor investors on a discretionary basis. One-third of the anchor portion is reserved for domestic mutual funds if valid bids are received at or above the anchor investor allocation price, and up to 5% of the net QIB portion is separately available proportionately to mutual funds.

Who receives shares and proceeds in the Acme India offer?

Acme India will issue up to 54.07 lakh new shares in the fresh issue, while promoter selling shareholders will sell up to 8.02 lakh existing shares in the offer for sale. The document separates those components but leaves their aggregate rupee values blank because the public-offer price has not been finalised. The pages supplied do not specify the proposed use of fresh-issue proceeds.

The 3.14 lakh shares set aside for the market maker are part of the 62.09 lakh-share offer, but have a separate function from the net offer to the public. The remaining 58.94 lakh shares are divided among QIBs, non-institutional investors and individual investors under the stated allocation framework. Acme India describes the market-maker reservation and net offer as 5.06% and 25.11%, respectively, of post-offer paid-up equity share capital.

The company reported only one completed pre-offer transaction in these pages: the Rs 20.52 crore private placement at Rs 190 a share. That price included Rs 180 of premium over the Rs 10 face value. It does not establish the book-built public-offer price, because the offer document continues to show that price as Rs [*].

How will Acme India allocate the public shares?

Acme India will allocate shares under the BSE SME book-building framework, subject to valid bids at or above the eventual offer price. QIB allotment, excluding any anchor investor portion, is stated to be proportionate. For individual investors, allotment to each bidder will not be less than the maximum bid lot, subject to available shares, with remaining shares allotted proportionately.

The non-institutional investor category has a minimum 8,85,600 shares. One-third of that portion is reserved for applications above two lots and up to an application amount of Rs 10 lakh, while two-thirds is reserved for applications above Rs 10 lakh. If either subcategory is undersubscribed, its unused shares may be allocated to bidders in the other non-institutional subcategory.

Acme India says undersubscription in any category other than the QIB portion may be met through spill-over from another category or combination of categories. Such reallocation is subject to applicable law and the discretion of Acme India, the book running lead managers and the designated stock exchange. The source does not state a final trading lot because that field remains marked as unspecified.

Non-anchor bids are to be made through the Application Supported by Blocked Amount, or ASBA, process. Under ASBA, a self-certified syndicate bank blocks the full bid amount in the applicant's bank account rather than collecting it when the application is submitted. The document says individual investors must bid for two lots and describes the minimum application size as above Rs 2 lakh, but does not give a final share count because the lot size and offer price are blank.

Why is Acme India using the BSE SME route?

Acme India proposes to list on BSE SME under Regulation 229(2) of Chapter IX of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. The prospectus states that its post-offer paid-up capital will be at least Rs 10 crore and below Rs 25 crore, which is the capital range cited for this SME offer route. The offer is also subject to final listing and trading approval from the stock exchange after allotment.

The source identifies Rs 25 crore as a later threshold for a BSE SME-listed company that makes a further capital issue. Under Regulation 280(2), a company whose paid-up capital would rise beyond Rs 25 crore through a rights issue, preferential issue, bonus issue or similar issuance would generally migrate to the main board, subject to specified conditions. Those conditions include a postal-ballot special resolution and in-principle main-board approval.

A company with paid-up capital above Rs 10 crore but below Rs 25 crore may also seek voluntary migration if it obtains the required non-promoter shareholder approval. BSE's stated criteria include market capitalisation of at least Rs 25 crore, promoter holding of at least 20%, positive operating profit in two of the previous three financial years, positive profit after tax in the immediately preceding financial year and net worth of at least Rs 15 crore for the preceding two full financial years. These are eligibility criteria, not statements that Acme India has met them.

Conclusion

Acme India's revised structure combines up to 54.07 lakh newly issued shares, up to 8.02 lakh promoter-sale shares and a 3.14 lakh-share market-maker reservation within the 62.09 lakh-share offer. The Rs 20.52 crore placement at Rs 190 per share reduced the stated offer size and provides a recent disclosed transaction price, but it does not determine the final public-offer price.

The next matters disclosed in the offer document are the finalisation of the offer price and trading lot, valid bids for the 58.94 lakh-share net offer, allotment and BSE SME's final listing and trading approvals. Acme India states that the timetable is indicative and that commencement of trading remains at the stock exchange's discretion under applicable law.